About
Gibson Oncology acquired the Indenos to provide a noticeable positive impact on cancer patient’s lives in two critical areas. First, cancer resistance continues to emerge among almost all cancer patients whom initially responded to some form of treatment. Indenos were specifically designed to achieve high drug concentrations and remain within cancer cells for optimal anti-cancer activity, which reduces the chances that cancer cells’ can remove the anti-cancer drug to avoid its own destruction – thus, Indenos fight cancer resistance. Second, Indenos have a favorable side effect profile so that cancer patients experience a better quality of life during treatment with no grade 3 or 4 diarrhea and much less grade 3 and 4 neutropenia. They believe, therefore, that their goal of Being Tough on Cancer, not on Patients, can be achieved through these novel anti-cancer drugs, and their planned Phase II trials are well-positioned for treating resistant cancers in children and adults.
Team & affiliation
Founders: [object Object], [object Object], [object Object], [object Object].
Region context
Gibson Oncology is one of 7 Biotechnology companies we track in undefined, based in Miami — about 2% of the region's 286 startups.